Search Results

Axsome Therapeutics, Inc. announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder.

Paradigm announced results from a collaboration with Altru Health System (Altru) to improve the efficiency of its clinical research program and expand the availability of clinical research as a care option for patients spanning 46 locations across a rural catchment area of over 4,000 square miles in North Dakota and Minnesota.

NeuroSense Therapeutics Ltd. reported statistically significant results from the 12-month data analysis of the PARADIGM Phase 2b study evaluating PrimeC in people living with Amyotrophic Lateral Sclerosis.

NeuroSense Therapeutics Ltd. announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced financial results for the quarter ended March 31, 2024.